Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Asper Biotech's LHON and Alström Syndrome Tests

Premium

Asper Biotech recently launched a test for Leber hereditary optic neuropathy, or LHON, a disease characterized by optic nerve dysfunction that leads to painless, subacute loss of central vision. It is caused by mutations in mitochondrial DNA and is transmitted by maternal inheritance.

Asper's LHON genetic test can detect all three primary mutations associated with LHON. The test is available as a service that includes DNA extraction, genotyping by array-based primer extension, and data interpretation.

Asper also recently added 13 markers to its array for Alström syndrome. The test surveys the ALMS1 gene for mutations. Alström syndrome is characterized by cone-rod dystrophy, obesity, progressive sensorineural hearing impairment, dilated cardiomyopathy, insulin resistance syndrome, developmental delay, and progressive hepatic and renal dysfunction. The syndrome is rare. According to Alström Syndrome International, about 800 cases of Alström syndrome have been identified worldwide.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.